|
Farrow et al. [30]
|
612
|
687a
|
Population based
|
>1 tablet/week during >6 months. 1 year lag time
|
Personal Interview
|
Aspirin (31%)
|
0.76
|
0.60–0.97
|
| |
610
| | | | |
NA-NSAIDs (13%)
|
0.79
|
0.56–1.10
|
|
Akre et al. [22]
|
480
|
1,055a
|
Population based
|
>30 tablets/month. 2 years lag time
|
Personal Interview
|
Aspirin (3%)
|
0.8
|
0.7–1.1
|
| | | | | | |
NA-NSAIDs†
|
1.1
|
0.6–1.4
|
|
Zaridze et al. [48]
|
448
|
610a
|
Hospital based
|
>2 days/week for >6 months
|
In-hospital Questionnaire
|
Aspirin (14%)
|
0.60
|
0.41–0.90
|
| | | | | | |
NSAIDs (17%)
|
0.65
|
0.45–0.93
|
|
Langman et al. [36]
|
613
|
1,837a
|
Population based
|
>7 prescriptions during months 13–36 before index date
|
Automated Database
|
NSAIDs (8%)
|
0.51
|
0.33–0.79
|
|
Coogan et al. [26]
|
250
|
5,883a
|
Hospital based
|
>4 days/week for >3 months. Continuing use during 1 year of lag time
|
Personal Interview
|
NSAIDs (7%)
|
0.3
|
0.1–0.6
|
|
Thun et al. [46]
|
266
|
635,031b
|
Cohort
|
More than 16 times per month for at least one year
|
Mailed Questionnaire
|
Aspirin (11%)
|
0.53
|
0.34–0.81
|
|
Schreinemachers et al. [43]
|
39
|
12,668b
|
Cohort
|
Ever use of aspirin in the 30 days prior to start date
|
Personal Interview
|
Aspirin (59%)
|
0.93
|
0.49–1.74
|
